SAMIL PHARMACEUTICAL Files Corporate Governance Report... Multiple Areas for Improvement Identified Including Late Shareholder Meeting Notice and No Dividends
SAMIL PHARMACEUTICAL disclosed its 2025 corporate governance report, acknowledging non-compliance with several key indicators and outlining improvement plans.
The company provided shareholder meeting notice only 2 weeks prior (recommended 4 weeks) and plans to expedite settlement procedures to meet the 4-week target.
No cash dividends have been paid for the past 3 fiscal years (2023-2025), and no mid-to-long-term shareholder return policy exists, citing investment needs in Vietnamese subsidiaries.
The board consists of 4 inside and 3 outside directors (43% independent); the CEO serves as board chair. No cumulative voting, no separate outside director meetings.
The audit committee comprises 3 outside directors but failed to hold quarterly meetings with external auditors without management. Internal audit function is not directly under the audit committee.
No formal CEO succession policy exists; candidates are reviewed by the board on an ad-hoc basis. No documented shareholder protection policy for major corporate events.
Electronic voting is available, but paper voting is not. No shareholder proposals were received; proposal procedures are not clearly communicated on the website.
[AI Overall Assessment]This report transparently discloses governance practices, which is positive. However, weaknesses in shareholder rights protection and board independence are evident. Prolonged dividend suspension and lack of return policy may reduce investment appeal; governance improvement speed is a key factor for medium-to-long-term stock performance.